Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa

ABSTRACT Evidence is mounting in support of the inoculum effect (i.e., slow killing at large initial inocula [CFUo]) for numerous antimicrobials against a variety of pathogens. Our objectives were to (i) determine the impact of the CFUo of Pseudomonas aeruginosa on ceftazidime activity and (ii) to develop and validate a pharmacokinetic/pharmacodynamic (PKPD) mathematical model accommodating a range of CFUo. Time-kill experiments using ceftazidime at seven concentrations up to 128 mg/liter (MIC, 2 mg/liter) were performed in duplicate against P. aeruginosa PAO1 at five CFUo from 105 to 109 CFU/ml. Samples were collected over 24 h and fit by candidate models in NONMEM VI and S-ADAPT 1.55 (all data were comodeled). External model qualification integrated data from eight previously published studies. Ceftazidime displayed approximately 3 to 4 log10 CFU/ml net killing at 106.2 CFUo and concentrations of 4 mg/liter (or higher), less than 1.6 log10 CFU/ml killing at 107.3 CFUo, and no killing at 108.0 CFUo for concentrations up to 128 mg/liter. The proposed mechanism-based model successfully described the inoculum effect and the concentration-independent lag time of killing. The mean generation time was 28.3 min. The effect of an autolysin was assumed to inhibit successful replication. Ceftazidime concentrations of 0.294 mg/liter stimulated the autolysin effect by 50%. The model was predictive in the internal cross-validation and had excellent in silico predictive performance for published studies of P. aeruginosa ATCC 27853 for various CFUo. The proposed PKPD model successfully described and predicted the pronounced inoculum effect of ceftazidime in vitro and integrated data from eight literature studies to support translation from time-kill experiments to in vitro infection models.

[1]  W. Liu,et al.  Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents , 1990, Antimicrobial Agents and Chemotherapy.

[2]  M. Barclay,et al.  The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro. , 1996, The Journal of antimicrobial chemotherapy.

[3]  A. Tomasz Penicillin-binding proteins and the antibacterial effectiveness of beta-lactam antibiotics. , 1986, Reviews of infectious diseases.

[4]  A. Vinks,et al.  Relationship Between Minimum Inhibitory Concentration and Stationary Concentration Revisited , 2005, Clinical pharmacokinetics.

[5]  P. Davey,et al.  The inoculum effect with gram-negative bacteria in vitro and in vivo. , 1987, The Journal of antimicrobial chemotherapy.

[6]  M. Page,et al.  Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae , 2007, Antimicrobial Agents and Chemotherapy.

[7]  M. Barclay,et al.  Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro , 1995, Antimicrobial agents and chemotherapy.

[8]  J. Mouton,et al.  Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model , 1994, Antimicrobial Agents and Chemotherapy.

[9]  D. Stevens,et al.  Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. , 1993, The Journal of infectious diseases.

[10]  M Davidian,et al.  Estimating data transformations in nonlinear mixed effects models. , 2000, Biometrics.

[11]  P. Grossi,et al.  Treatment of Pseudomonas aeruginosa infection in critically ill patients , 2006, Expert review of anti-infective therapy.

[12]  T. Nakae,et al.  Enhancement of the mexAB-oprM Efflux Pump Expression by a Quorum-Sensing Autoinducer and Its Cancellation by a Regulator, MexT, of the mexEF-oprN Efflux Pump Operon in Pseudomonas aeruginosa , 2004, Antimicrobial Agents and Chemotherapy.

[13]  S. Palmer,et al.  Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model , 1995, Antimicrobial agents and chemotherapy.

[14]  E. Greenberg,et al.  A network of networks: quorum-sensing gene regulation in Pseudomonas aeruginosa. , 2006, International journal of medical microbiology : IJMM.

[15]  M. Levison,et al.  Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula. , 1995, The Journal of antimicrobial chemotherapy.

[16]  D. Orr,et al.  Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. , 1983, The Journal of antimicrobial chemotherapy.

[17]  Y. Yano,et al.  Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. , 1998, Journal of pharmaceutical sciences.

[18]  Frieder Keller,et al.  Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  R. Eng,et al.  Inoculum effect of new beta-lactam antibiotics on Pseudomonas aeruginosa , 1984, Antimicrobial Agents and Chemotherapy.

[20]  Jonathan R Edwards,et al.  Overview of nosocomial infections caused by gram-negative bacilli. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  H. Derendorf,et al.  Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. , 2007, International journal of antimicrobial agents.

[22]  D. Haas,et al.  Impact of quorum sensing on fitness of Pseudomonas aeruginosa. , 2006, International journal of medical microbiology : IJMM.

[23]  N. Masuda,et al.  Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosa , 2000, Antimicrobial Agents and Chemotherapy.

[24]  H. Mattie,et al.  Pharmacokinetic and pharmacodynamic models of the antistaphylococcal effects of meropenem and cloxacillin in vitro and in experimental infection , 1997, Antimicrobial agents and chemotherapy.

[25]  S. Landesman,et al.  Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa , 1980, Antimicrobial Agents and Chemotherapy.

[26]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[27]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[28]  K. Tateda,et al.  Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa. , 2007, International journal of antimicrobial agents.

[29]  A. Tomasz From penicillin-binding proteins to the lysis and death of bacteria: a 1979 view. , 1979, Reviews of infectious diseases.

[30]  R. Hancock,et al.  Identification of a penicillin-binding protein 3 homolog, PBP3x, in Pseudomonas aeruginosa: gene cloning and growth phase-dependent expression , 1997, Journal of bacteriology.

[31]  M. Leider Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[32]  I. Shalit,et al.  In vitro antibacterial activities of antibiotics against Pseudomonas aeruginosa in peritoneal dialysis fluid , 1985, Antimicrobial Agents and Chemotherapy.

[33]  D. Livermore Radiolabelling of penicillin-binding proteins (PBPs) in intact Pseudomonas aeruginosa cells: consequences of beta-lactamase activity by PBP-5. , 1987, The Journal of antimicrobial chemotherapy.

[34]  P. McNamara,et al.  Mechanism-Based Pharmacodynamic Models of Fluoroquinolone Resistance in Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[35]  A. Tomasz,et al.  Mechanism of phenotypic tolerance of nongrowing pneumococci to beta-lactam antibiotics. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[36]  D. Ruppert,et al.  Transformation and Weighting in Regression , 1988 .

[37]  S. Keil,et al.  Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models , 1995, Antimicrobial agents and chemotherapy.

[38]  P. Verhulst Recherches mathématiques sur la loi d’accroissement de la population , 2022, Nouveaux mémoires de l'Académie royale des sciences et belles-lettres de Bruxelles.

[39]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.

[40]  Max Salfinger,et al.  Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. , 2004, The Journal of infectious diseases.

[41]  V. Tam,et al.  Comparison of β-lactams in counter-selecting resistance of Pseudomonas aeruginosa , 2005 .

[42]  D. Denning,et al.  Effect of Neutropenia and Treatment Delay on the Response to Antifungal Agents in Experimental Disseminated Candidiasis , 2006, Antimicrobial Agents and Chemotherapy.

[43]  W. M. Kirby BACTERIOSTATIC AND LYTIC ACTIONS OF PENICILLIN ON SENSITIVE AND RESISTANT STAPHYLOCOCCI. , 1945, The Journal of clinical investigation.

[44]  S. Diggle,et al.  The Pseudomonas aeruginosa quinolone signal molecule overcomes the cell density‐dependency of the quorum sensing hierarchy, regulates rhl‐dependent genes at the onset of stationary phase and can be produced in the absence of LasR , 2003, Molecular microbiology.

[45]  Jyoti Gupta,et al.  Expression of the las and rhl quorum-sensing systems in clinical isolates of Pseudomonas aeruginosa does not correlate with efflux pump expression or antimicrobial resistance. , 2006, The Journal of antimicrobial chemotherapy.

[46]  E. Tuomanen Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria. , 1986, Reviews of infectious diseases.

[47]  R. Eng,et al.  Inoculum effect of beta-lactam antibiotics on Enterobacteriaceae , 1985, Antimicrobial Agents and Chemotherapy.

[48]  P. Benfield,et al.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. , 1988, Drugs.

[49]  I. Wiegand,et al.  Development of Resistance in Wild-Type and Hypermutable Pseudomonas aeruginosa Strains Exposed to Clinical Pharmacokinetic Profiles of Meropenem and Ceftazidime Simulated In Vitro , 2007, Antimicrobial Agents and Chemotherapy.

[50]  A. Tomasz Penicillin-Binding Proteins and the Antibacterial Effectiveness of β-Lactam Antibiotics , 1986 .

[51]  I. Brook Inoculum effect. , 1989, Reviews of infectious diseases.

[52]  P. Lebecque,et al.  Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[53]  H. Eagle THE EFFECT OF THE SIZE OF THE INOCULUM AND THE AGE OF THE INFECTION ON THE CURATIVE DOSE OF PENICILLIN IN EXPERIMENTAL INFECTIONS WITH STREPTOCOCCI, PNEUMOCOCCI, AND TREPONEMA PALLIDUM , 1949, The Journal of experimental medicine.

[54]  Patrick F. Smith,et al.  Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype , 2008, Antimicrobial Agents and Chemotherapy.

[55]  Robert Leary,et al.  Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. , 2005, The Journal of infectious diseases.

[56]  K. Tateda,et al.  Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa , 2007 .

[57]  Robert Leary,et al.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. , 2003, The Journal of clinical investigation.

[58]  E. Bailey,et al.  Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model , 1992, Antimicrobial Agents and Chemotherapy.

[59]  T. Nakae,et al.  A Quorum‐Sensing Autoinducer Enhances the mexAB‐oprM Efflux‐Pump Expression without the MexR‐Mediated Regulation in Pseudomonas aeruginosa , 2004, Microbiology and immunology.

[60]  D. Peters,et al.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. , 1995, Drugs.

[61]  P. Tulkens,et al.  Comparative Stability Studies of Antipseudomonal β-Lactams for Potential Administration through Portable Elastomeric Pumps (Home Therapy for Cystic Fibrosis Patients) and Motor-Operated Syringes (Intensive Care Units) , 2002, Antimicrobial Agents and Chemotherapy.

[62]  A. Vinks,et al.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion , 1997, Antimicrobial agents and chemotherapy.

[63]  Alan Forrest,et al.  Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin , 2004, Antimicrobial Agents and Chemotherapy.

[64]  W. Craig,et al.  The inoculum effect: fact or artifact? , 2004, Diagnostic microbiology and infectious disease.

[65]  T. Beveridge,et al.  A major autolysin of Pseudomonas aeruginosa: subcellular distribution, potential role in cell growth and division and secretion in surface membrane vesicles , 1996, Journal of bacteriology.